Fig. 5: PKLR rescues ZBTB10-suppressed malignancy of PCa. | Cell Death & Disease

Fig. 5: PKLR rescues ZBTB10-suppressed malignancy of PCa.

From: Pyruvate kinase L/R links metabolism dysfunction to neuroendocrine differentiation of prostate cancer by ZBTB10 deficiency

Fig. 5

A, B Proliferation in C4-2 cells stably transfected with an empty vector (EV) or PKLR cDNA vector (A) or in PC3 cells with a non-target control (NC) or PKLR shRNA vector transfection (B). n = 8 per group. * vs. the EV (A) or NC (B); by a one-way ANOVA. C, D Sphere formation of C4-2 (C) and PC3 (D) cells with PKLR overexpression (C) or PKLR-knockdown (KD) (D), respectively. n = 8 per group. * vs. the EV (C) or NC (D); by a one-way ANOVA. E Protein levels of PKLR in C4-2 or PC3 cells with PKLR overexpression or PKLR-KD. F, G Proliferation of LNCaP and C4-2 cells stably transfected with the EV, ZBTB10, or ZBTB10+PKLR cDNA vector. n = 8 per group. * vs. the EV; # vs. ZBTB10; by a two-way ANOVA. H Sphere formation of LNCaP and C4-2 cells stably transfected with the EV, ZBTB10, or ZBTB10+PKLR cDNA vector. n = 8 per group. * vs. the EV; # vs. ZBTB10; by a two-way ANOVA. I, J Relative migration (I) and invasion (J) of LNCaP and C4-2 cells stably transfected with the EV, ZBTB10, or ZBTB10 + PKLR cDNA vector. n = 5 per group. * vs. the EV; # vs. ZBTB10; by a two-way ANOVA. Quantification of proliferation, sphere formation, migration, and invasion assays presented as the mean ± SEM from three biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001. K, L Relative PKLR, ZBTB10, proliferation marker, and EMT marker mRNA levels in LNCaP (K) and C4-2 (L) cells expressing the EV, PKLR, or ZBTB10 + PKLR cDNA vector. * vs. the EV; # vs. ZBTB10; by a two-way ANOVA. Quantification of mRNA is presented as the mean ± SEM from three biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001.

Back to article page